2013-2019年医疗保险受益人中2型糖尿病合并心力衰竭、动脉粥样硬化性心血管疾病和慢性肾脏病者SGLT2抑制剂与GLP-1受体激动剂使用的种族和民族差异
该回顾性队列研究利用2013-2019年医疗保险按服务付费数据,纳入65岁及以上2型糖尿病起始二线治疗的老年人,分析合并心力衰竭、动脉粥样硬化性心血管疾病、慢性肾脏病或无记录心肾疾病者中SGLT2抑制剂和GLP-1受体激动剂使用的种族和民族差异。结果显示,黑人参与者起始SGLT2抑制剂和GLP-1受体激动剂的几率低于白人,西班牙裔参与者起始GLP-1受体激动剂的几率低于白人,而起始无心血管肾脏获益的DPP4抑制剂的几率高于白人。
要点
- 黑人合并心衰、ASCVD、CKD或无记录心肾疾病者起始SGLT2抑制剂的调整OR分别为0.65、0.67、0.68和0.76,均低于白人。
- 西班牙裔合并心衰、ASCVD、CKD和无记录心肾疾病者起始GLP-1受体激动剂的调整OR分别为0.89、0.84、0.84和0.75,均低于白人。
- 所有队列中参与者起始DPP4抑制剂的几率高于白人,心衰、ASCVD和CKD队列的调整OR分别为1.25、1.36和1.32。
核心结论
- 与白人参与者相比,黑人参与者起始SGLT2抑制剂的差异明显,黑人和西班牙裔参与者起始GLP-1受体激动剂的差异明显。
- 该研究凸显2型糖尿病管理正在演变,同时强调历史性不平衡已显示出减轻迹象。
研究设计与样本
- 使用2013-2019年医疗保险按服务付费数据的回顾性队列研究。
- 纳入65岁及以上2型糖尿病起始二线治疗(SGLT2抑制剂、GLP-1受体激动剂、DPP4抑制剂和磺脲类)的老年人。
- 按是否合并心力衰竭、动脉粥样硬化性心血管疾病、慢性肾脏病或无记录心肾疾病分为4个队列。
- 参与者分类为非西班牙裔白人、非西班牙裔黑人和西班牙裔。
- 采用多项回归模型,调整社会人口学、临床和县级特征,评估各队列中起始SGLT2抑制剂或GLP-1受体激动剂的比值比。
主要发现
- 黑人合并心衰、ASCVD、CKD或无记录心肾疾病者起始SGLT2抑制剂的调整OR分别为0.65(95%CI 0.61, 0.68)、0.67(95%CI 0.64, 0.69)、0.68(95%CI 0.64, 0.72)和0.76(95%CI 0.74, 0.79),均低于白人。
- 差异从2013年低50-60%改善至2019年低17-18%。
- 黑人参与者中GLP-1受体激动剂使用呈现相似模式。
- 西班牙裔合并心衰和CKD者起始SGLT2抑制剂的几率与白人相似,但合并ASCVD者低6%(OR 0.94 [95%CI 0.91, 0.98])。
- 西班牙裔合并心衰、ASCVD、CKD和无记录心肾疾病者起始GLP-1受体激动剂的调整OR分别为0.89(95%CI 0.84, 0.94)、0.84(95%CI 0.81, 0.87)、0.84(95%CI 0.80, 0.89)和0.75(95%CI 0.72, 0.78),均低于白人。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The aim of this study was to investigate racial and ethnic disparities in the use of sodium-glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor antagonists (GLP-1RAs) among older adults with type 2 diabetes and cardiorenal conditions. METHODS: Using Medicare fee-for-service data (2013-2019), this retrospective cohort study identified older adults (≥65 years) with type 2 diabetes initiating second-line therapies (SGLT2is, GLP1-RAs, dipeptidyl peptidase-4 inhibitors [DPP4is] and sulfonylureas [SUs]) with (1) heart failure (HF), (2) atherosclerotic cardiovascular disease (ASCVD), (3) chronic kidney disease (CKD) and (4) no recorded cardiorenal conditions. Participants were classified as non-Hispanic White, non-Hispanic Black and Hispanic. Multinomial regressions, adjusting for sociodemographic, clinical and county-level characteristics, were used to model the odds of initiating SGLT2is or GLP-1RAs within each cohort. RESULTS: Black participants with HF, ASCVD, CKD or no recorded cardiorenal conditions had 35% (adjusted OR 0.65 [95% CI 0.61, 0.68]), 33% (0.67 [0.64, 0.69]), 32% (0.68 [0.64, 0.72]) and 24% (0.76 [0.74, 0.79]) lower odds of initiating SGLT2is, respectively, than White participants. Disparities ameliorated from 50-60% lower odds in 2013 to 17-18% in 2019. Similar patterns were observed for GLP-1RA uptake among Black participants. By contrast, Hispanic participants had similar odds of SGLT2i initiation in the HF and CKD cohorts as White participants, but 6% (0.94 [0.91, 0.98]) lower odds in the ASCVD cohort. Notable disparities for Hispanic participants compared with White participants were observed for GLP-1RA uptake in the HF, ASCVD, CKD and no cardiorenal conditions cohorts: 11% (0.89 [0.84, 0.94]), 16% (0.84 [0.81, 0.87]), 16% (0.84 [0.80, 0.89]) and 25% (0.75 [0.72, 0.78]) lower odds, respectively. Participants had greater odds than White participants of initiating DPP4is, which confer no cardiorenal benefits, across all cohorts (HF 1.25 [1.19, 1.31]; ASCVD 1.36 [1.32, 1.40]; CKD 1.32 [1.26, 1.38). Adjustment for social determinants of health did not meaningfully change the study findings. CONCLUSIONS/INTERPRETATION: Compared with White participants, disparities in the uptake of SGLT2is were evident for Black participants, and in the uptake of GLP-1RAs for both Black and Hispanic participants. This study highlights how type 2 diabetes management is evolving, while underscoring historical imbalances that have shown signs of abatement.
引用
- Wang E, Patorno E, Khosrow-Khavar F, et al. Racial and ethnic disparities in the uptake of SGLT2is and GLP-1RAs among Medicare beneficiaries with type 2 diabetes and heart failure, atherosclerotic cardiovascular disease and chronic kidney disease, 2013-2019. Diabetologia. 2024. PMID: 39514094. doi:10.1007/s00125-024-06321-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。